GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bio Path Holdings
Shares of Bio-Path, an early-stage oncology biotech, are a highly speculative bet on its unique RNA drug delivery technology. Their price is driven not by financial performance, but by clinical trial news.
Share prices of companies in the market segment - Cancer blood
Bio-Path Holdings develops cancer treatments based on its unique technology for delivering RNA therapeutics directly to tumor cells. We've categorized it under "Blood Cancer." The chart below shows how investors value innovative oncology platforms.
Broad Market Index - GURU.Markets
Bio-Path Holdings is an oncology company developing drugs based on its DNAbilong platform that target cancer-causing proteins. Its unique technology makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Bio-Path compares to it.
Change in the price of a company, segment, and market as a whole per day
BPTH - Daily change in the company's share price Bio Path Holdings
For Bio-Path Holdings, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer blood
Bio-Path Holdings develops cancer treatments based on a unique RNA therapeutic delivery technology. Oncology, especially in the early stages of development, is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for assessing BPTH's risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Bio-Path Holdings is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bio Path Holdings
Bio-Path Holdings' year-to-date performance is the story of its unique RNA therapy delivery technology. Its 12-month market cap is entirely dependent on clinical trial data from its blood cancer treatments. The success of its DNAbilize® platform could offer a new way to combat difficult-to-treat cancers.
Annual dynamics of market capitalization of the market segment - Cancer blood
As an early-stage biotech company, Bio-Path is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its RNA therapy delivery platform. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bio-Path Holdings, a company developing technology to suppress cancer-causing proteins at the RNA level, exemplifies cutting-edge science. Its annual market capitalization growth is entirely dependent on the success of its unique platform in clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bio Path Holdings
Bio-Path is a clinical-stage oncology company with a unique drug delivery technology. Its monthly performance directly reflects news from its clinical trials. Any data from its programs prompts an immediate reaction from investors.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Bio-Path Holdings is developing a unique technology for delivering RNA therapy for cancer treatment. This is a cutting-edge, but highly risky approach. The chart below reflects how investors assessed the prospects of this experimental platform, where the potential for breakthrough is juxtaposed with a high probability of failure.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bio-Path Holdings is developing a unique drug delivery technology for cancer treatment. It is a clinical-stage biotech company. Its stock price will depend entirely on whether this new technology proves its worth in human trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bio Path Holdings
Shares of Bio-Path Holdings, a clinical-stage oncology company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their unique drug delivery technology. The chart below is a prime example of how short-term scientific data and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Bio-Path Holdings is developing a unique drug delivery technology for cancer treatment. It's a risky but potentially breakthrough approach. The chart clearly demonstrates how the company's shares move at their own pace, driven by lab news rather than general market trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bio-Path Holdings is a biotech company whose fate depends on scientific data. This chart clearly demonstrates how out of sync its weekly performance can be with the broader market. A single piece of news about clinical trials can cause huge swings.
Market capitalization of the company, segment and market as a whole
BPTH - Market capitalization of the company Bio Path Holdings
The valuation of Bio-Path Holdings, Inc. on the chart is a bet on its unique DNA-bilateral therapy technology for blood cancer. This clinical-stage biotech's market cap depends on whether its approach proves effective. The dynamics illustrate the high risk and potential of this new scientific platform.
BPTH - Share of the company's market capitalization Bio Path Holdings within the market segment - Cancer blood
Bio-Path's market share in oncology is based on its unique DNAbilomics® technology, which enables drug delivery directly to cancer cells without affecting healthy cells. Its market share is a bet on the potential of this platform to create safer and more effective treatments for blood cancers.
Market capitalization of the market segment - Cancer blood
Here's a chart of the total market capitalization of biotech companies developing antisense therapies. Bio-Path Holdings is one of the players in this field. The chart's dynamics reflect the high volatility and risks associated with clinical trials of this cutting-edge technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of a unique "antisense" technology for cancer treatment. Bio-Path Holdings' market cap is a bet on its platform, which blocks the production of "cancer" proteins. The line shows how a bold scientific idea is competing for its share of the future of oncology.
Book value capitalization of the company, segment and market as a whole
BPTH - Book value capitalization of the company Bio Path Holdings
Bio-Path Holdings' book value is its scientific capital. The chart below reflects the valuation of its unique DNAbilomics® platform for developing antisense cancer therapies. The pipeline's growth signals success in clinical trials, which are the primary tangible embodiment of this biotech company's value.
BPTH - Share of the company's book capitalization Bio Path Holdings within the market segment - Cancer blood
Bio-Path Holdings' core assets are its laboratories developing a unique platform for delivering RNA therapy directly to cancer cells. The chart shows the company's share of this cutting-edge scientific infrastructure, which forms the physical basis for its innovative approach to cancer treatment.
Market segment balance sheet capitalization - Cancer blood
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Bio-Path Holdings, as a development company, has a more streamlined model. Its value lies in its unique scientific platform, not in the scale of its production.
Book value of all companies included in the broad market index - GURU.Markets
Bio-Path Holdings is developing a unique lipid-based drug delivery technology for cancer treatment. Its assets are not factories, but a patented platform that enables the "packaging" of RNA therapies. The chart below shows the material weight behind this innovative "postal service" for genes.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bio Path Holdings
Bio-Path Holdings is developing a unique technology for delivering drugs directly to cancer cells. Its value lies in this platform. The chart below is a visualization of the venture capital bet. Market capitalization is not linked to the balance sheet and reflects investors' faith in the breakthrough potential of its approach.
Market to book capitalization ratio in a market segment - Cancer blood
Bio-Path Holdings, Inc. is a biotech company developing an RNA-based cancer treatment platform. Its value is based on the potential of this technology. This chart shows how its market valuation, reflecting its hopes for a breakthrough in oncology, is many times greater than its current assets.
Market to book capitalization ratio for the market as a whole
Bio-Path Holdings develops drugs for the treatment of blood cancers using a unique RNA-based therapeutic delivery technology. The market valuation shown in this chart is based on the potential of their scientific platform. The dynamics reflect expectations for clinical trials.
Debts of the company, segment and market as a whole
BPTH - Company debts Bio Path Holdings
Bio-Path, a clinical-stage biotech company, is using raised capital to develop its unique RNA therapy delivery technology. This chart shows how the company is spending its funds on early clinical trials for blood cancer, a high-risk endeavor.
Market segment debts - Cancer blood
Bio-Path Holdings is developing a unique antisense drug delivery technology for cancer treatment. This chart shows how its financial structure, with virtually no debt, reflects the early and high-risk stage of its development, which is financed exclusively by equity capital until the technology reaches later stages of clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bio Path Holdings
Bridge Investment Group is a real estate and alternative investment management company. It uses investor capital and debt financing to acquire assets. The chart shows its proprietary corporate financial structure, which supports its extensive investment activities.
Market segment debt to market segment book capitalization - Cancer blood
Bio-Path Holdings is a clinical-stage biotech company developing cancer treatments based on its DNA-based technology. This chart compares its debt load to the overall market capitalization of the oncology sector. It shows how the company finances its unique research and development efforts.
Debt to book value of all companies in the market
Bio-Path Holdings is developing a unique technology for delivering RNA therapy directly to cancer cells. This is an innovative approach in oncology. This graph of total market debt shows the overall risk appetite, which is important for a company raising capital for clinical trials of its cutting-edge, but unproven, platform.
P/E of the company, segment and market as a whole
P/E - Bio Path Holdings
For Bio-Path Holdings, a clinical-stage oncology company, the P/E ratio is not applicable. The company has no profit, and its valuation on this chart is arbitrary. The actual value is a speculative bet on the success of its unique technology for delivering drugs directly to cancer cells.
P/E of the market segment - Cancer blood
Bio-Path Holdings is developing a new class of anti-cancer drugs based on its DNAbilize® technology, which delivers nucleic acids into cells to suppress cancer-causing proteins. This chart shows the average valuation for the oncology sector, reflecting how investors evaluate risky but potentially breakthrough technology platforms.
P/E of the market as a whole
Bio-Path Holdings develops cancer treatments based on its unique DNAbilize® technology, which delivers nucleic acids directly into cells. This risk appetite chart helps understand how investors value biotech companies with innovative, yet early-stage, platforms.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bio Path Holdings
Bio-Path Holdings develops cancer treatments based on a unique RNA therapeutic delivery technology. This graph reflects market expectations for the success of this innovative approach. Future revenue depends on clinical trial results and commercial potential.
%20P%2FE%20Bio%20Path%20Holdings&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bio-Path-Holdings&v=1772592096566 "Chart of the company's future (projected) P/E Bio Path Holdings")
Future (projected) P/E of the market segment - Cancer blood
Bio-Path Holdings is developing a platform for targeted RNA-based cancer therapy. This chart reflects how investors view its unique, yet high-risk, scientific approach. It compares expectations for Bio-Path with those of other early-stage biotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772592096574 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Bio-Path Holdings is developing DNA-based therapies for the treatment of blood cancer. This is an innovative technology that requires significant investment. This chart, reflecting market optimism, demonstrates investor appetite for risk, which is vital for funding such cutting-edge, yet early-stage, developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772592096600 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bio Path Holdings
Bio-Path Holdings is a clinical-stage biotech company developing an RNA-based cancer therapy platform. Its financial performance is driven by clinical trial expenses. This chart illustrates the financial trajectory of the company, whose technology aims to suppress disease-causing proteins at the genetic level.
Profit of companies in the market segment - Cancer blood
Bio-Path Holdings develops cancer treatments based on its unique DNAbilize® technology, which delivers nucleic acids directly into cells. This graph, showing overall sector profitability, reflects the company's pursuit of breakthrough approaches. Success at Bio-Path's platform could lead to the creation of a new class of drugs and radically change the industry.
Overall market profit
Bio-Path Holdings develops DNA-based therapies for cancer treatment. Its technology targets disease-causing proteins at the genetic level. This innovative approach is currently in clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bio Path Holdings
Bio-Path Holdings develops cancer treatments based on its unique RNA delivery technology. Future revenue projections are speculative and depend entirely on the success of its clinical programs.
%20profit%20of%20the%20company%20Bio%20Path%20Holdings&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bio-Path-Holdings&v=1772592096662 "Graph of future (projected) profit of the company Bio Path Holdings")
Future (predicted) profit of companies in the market segment - Cancer blood
Bio-Path Holdings develops RNA-based therapeutics for the treatment of cancer, particularly leukemia. This chart shows future revenue expectations for the entire blood cancer segment. It allows one to assess how the company's innovative technology platform compares to the overall outlook for this competitive field of oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772592096676 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Bio-Path Holdings develops cancer treatments based on unique RNA technology. The company is in the clinical stage. This chart, reflecting investors' risk appetite, is of great importance to Bio-Path. Positive economic forecasts facilitate raising the capital needed to continue expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772592096687 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bio Path Holdings
Bio-Path Holdings is developing cancer treatments based on its unique DNA/RNA delivery technology. For a clinical-stage biotech company, this chart reflects pure potential. It shows how investors view its innovative platform, which has the potential to overcome the limitations of traditional treatments.
P/S market segment - Cancer blood
Bio-Path Holdings develops anti-cancer drugs based on its DNAbilize® platform, which uses antisense technology to inhibit cancer-causing proteins. This chart reflects the market's willingness to pay for biotech revenue, demonstrating confidence in Bio-Path's unique scientific platform and the potential of its developments.
P/S of the market as a whole
Bio-Path Holdings develops cancer treatments based on its DNAbilize platform, which delivers nucleic acids directly to cells. This chart, reflecting the average valuation, shows that investors value the company based on the potential of its unique scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bio Path Holdings
Bio-Path Holdings develops cancer treatments based on its unique DNA therapeutic delivery technology. This chart shows the market's estimate of its potential future revenue. It reflects investor confidence in its scientific platform and the commercial potential of its candidates if clinical trials are successful.
%20P%2FS%20Bio%20Path%20Holdings&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bio-Path-Holdings&v=1772592096742 "The graph of the company's future (projected) P/S Bio Path Holdings")
Future (projected) P/S of the market segment - Cancer blood
Bio-Path Holdings is developing a DNA therapy platform for cancer treatment. The chart shows the average estimated future revenue in the blood cancer sector. It helps understand how the market views Bio-Path's unique technology and its potential to create a new class of anti-cancer drugs, despite its early stage development and associated risks.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772592096767 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Bio-Path Holdings (BPTH) is developing an RNA therapy platform targeting blood cancers. Their future depends solely on the success of clinical trials. This general economic outlook has no bearing on their scientific developments, which could offer a new approach to cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772592096786 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bio Path Holdings
Bio-Path Holdings is a clinical-stage biotech company developing a unique technology for cancer treatment. It has no sales revenue. Its financial history is based on investments in research. The graph will reflect future revenue from licensing or partnerships for its drug candidates following successful trials.
Sales of companies in the market segment - Cancer blood
Bio-Path Holdings is developing an RNA-based targeted cancer therapy platform. Currently in the clinical stage, it has no revenue yet. Its future revenue will depend on the success of its innovative approach to treating various types of blood cancers and solid tumors.
Overall market sales
Bio-Path Holdings, Inc. is a biotech company developing drugs for the treatment of blood cancer using a unique delivery technology. Its success depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences the investment climate in biotech and the ability to attract capital to fund expensive R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bio Path Holdings
Bio-Path Holdings develops cancer treatments based on its unique RNA therapeutic delivery technology. Future revenue is dependent on the success of clinical trials. This graph reflects long-term expectations for its DNAbilize platform.
%20sales%20of%20the%20company%20Bio%20Path%20Holdings&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bio-Path-Holdings&v=1772592096877 "Schedule of future (projected) sales of the company Bio Path Holdings")
Future (projected) sales of companies in the market segment - Cancer blood
Bio-Path Holdings is developing targeted therapies based on DNA aptamers for the treatment of blood cancers and solid tumors. This chart shows the outlook for the blood cancer sector. It reflects the ongoing search for new mechanisms of action to combat cancer at the genetic level, which is the core of Bio-Path's technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772592096916 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
The biotech investment climate illustrated by this chart is important for Bio-Path Holdings. The company develops drugs to treat blood cancers. Its ability to fund lengthy and expensive clinical trials is directly dependent on the influx of capital into the industry, which increases with economic growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772592096945 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bio Path Holdings
Bio-Path Holdings develops drugs based on unique DNA therapeutic technology for the treatment of cancer. This chart reflects its current status as a research and development organization. Future profitability depends entirely on the success of clinical trials and the validation of its innovative drug delivery platform.
Market segment marginality - Cancer blood
Bio-Path Holdings develops cancer treatments based on its unique technology for delivering RNA therapeutics directly to cells. Profitability depends on the success of this innovative approach in clinical trials. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential and risks associated with Bio-Path's technology.
Market marginality as a whole
Bio-Path Holdings is developing a nucleic acid-based targeted cancer therapy platform. As an early-stage company, it is entirely dependent on capital raising. This chart reflects the overall investment climate and investor willingness to invest in high-risk but potentially breakthrough biotech projects in the preclinical or early clinical stages.
Employees in the company, segment and market as a whole
Number of employees in the company Bio Path Holdings
Bio-Path Holdings is developing cancer treatments based on its unique RNA therapeutic delivery technology. This graph shows a small team of scientists advancing their platform through clinical trials. A small team is typical for early-stage biotech companies, where the primary value lies in intellectual property.
Share of the company's employees Bio Path Holdings within the market segment - Cancer blood
Bio-Path Holdings develops drugs based on the unique DNAbilize technology, which delivers nucleic acids into cells to suppress cancer-causing proteins. This chart shows the company's share of the total number of scientists working in this cutting-edge field of oncology.
Number of employees in the market segment - Cancer blood
Bio-Path Holdings, Inc. is developing drugs based on its DNAbilize® platform, which delivers nucleic acids into cells to treat cancer. This chart, showing activity in the blood cancer treatment sector, is important. The growing number of scientists working on drug delivery technologies indicates the search for new ways to target difficult-to-reach targets.
Number of employees in the market as a whole
Bio-Path Holdings develops a unique drug delivery technology for cancer treatment. This total employment chart reflects the investment climate in the biotech sector. During periods of economic growth, as shown here, investors are more willing to fund companies with innovative, yet unproven, platforms that could transform treatment approaches.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bio Path Holdings (BPTH)
Bio-Path Holdings (BPTH) is a biotech company with a unique drug delivery platform (DNAbilize) for cancer treatment. It is an R&D company. Its value is derived from its intellectual capital (patents for the platform). This metric reflects the high market valuation of their science relative to their small staff.
%20of%20the%20company%20Bio%20Path%20Holdings%20(BPTH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bio-Path-Holdings-BPTH&v=1772592097398 "Chart of market capitalization per employee (in thousands of dollars) of the company Bio Path Holdings (BPTH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Bio-Path Holdings is developing a unique drug delivery technology for cancer treatment. It's an early-stage company whose value depends entirely on the success of its scientific platform. This metric clearly illustrates that in biotech, market capitalization reflects investors' hopes for a future breakthrough, not current performance.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772592097455 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Bio-Path Holdings develops cancer treatments based on a unique RNA therapeutic delivery technology. The company's market capitalization is based on its innovative platform. This chart shows a very high valuation per employee, as investors are betting on the breakthrough technology being developed by a small scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772592097494 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bio Path Holdings (BPTH)
Bio-Path Holdings is a biotech company developing a DNA therapeutic platform (DNAbilize) for the treatment of cancer, specifically leukemia. This is an early-stage R&D company. This chart shows the company's capital burn rate: how much (negative profit) the company spends on each scientist to test its unique technology in clinical trials.
%20Chart%20Bio%20Path%20Holdings%20(BPTH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bio-Path-Holdings-BPTH&v=1772592097545 "Company Profit Per Employee (in thousands of dollars) Chart Bio Path Holdings (BPTH)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Bio-Path Holdings is developing drugs to treat blood cancers based on its unique RNA therapy technology. For an early-stage biotech company, this graph reflects resource efficiency. Investors analyze it in the context of clinical trial data, which determines the future value of the technology and the company.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772592097579 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Bio-Path Holdings (BPTH) is a biopharmaceutical company developing the DNAbilance platform for the treatment of blood cancer. It is a clinical-stage R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of oncology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772592097629 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bio Path Holdings (BPTH)
Bio-Path Holdings is developing a platform for targeted RNA-based cancer therapy. Currently in clinical trials, the company has no sales revenue. This chart is important as a benchmark, demonstrating the potential of their unique technology if successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bio-Path-Holdings-BPTH&v=1772592097748 "Sales chart per company employee Bio Path Holdings (BPTH)")
Sales per employee in the market segment - Cancer blood
Bio-Path Holdings is a biotech R&D company developing the DNA-building platform (DNAbilize) for the treatment of blood cancer. This is a clinical-stage R&D company. This chart clearly shows that the company has no commercial revenue. The productivity of their scientific team is measured solely by progress in clinical trials.
Sales per employee for the market as a whole
Yext (YEXT) provides a SaaS platform that allows businesses (restaurants, banks, retailers) to manage their digital information (addresses, hours, menus) across hundreds of websites and services (Google Maps, Yelp, Alexa) from a single location. This graph demonstrates the effectiveness of the SaaS model. Yext's platform automates previously manual tasks. This scalable solution allows Yext to serve thousands of customers.
Short shares by company, segment and market as a whole
Shares shorted by company Bio Path Holdings (BPTH)
Bio-Path (BPTH) is developing a unique technology for delivering RNA drugs for cancer treatment. This chart shows the volume of short positions. The short positions reflect high skepticism about this new, unproven scientific platform.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bio-Path-Holdings-BPTH&v=1772592097993 "Short Shares Chart for the Company Bio Path Holdings (BPTH)")
Shares shorted by market segment - Cancer blood
Bio-Path (BPTH) is developing a DNA therapy platform (antisense) for the treatment of oncological diseases, including blood cancers. The chart below shows the overall short position in the oncology biotech sector, demonstrating the general investor skepticism regarding the success of risky clinical trials.
Shares shorted by the overall market
Bio-Path is an early-stage biotech developing RNA therapy for blood cancer. It's complex science. This chart illustrates the general market "fear." When investors panic, they're unwilling to fund such long-term scientific projects. They see their cash being burned and sell off their shares, fearing the company won't survive to see success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bio Path Holdings (BPTH)
Bio-Path Holdings (BPTH) is developing a unique RNA therapy delivery technology (DNAbilize) for the treatment of blood cancer. This is a complex and high-risk area of biotech. This chart measures the strength of speculative moves. It shows when short bursts of enthusiasm (above 70) are fading or when a decline (below 30) attracts speculative buyers.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bio-Path-Holdings-BPTH&v=1772592098055 "RSI 14 indicator chart for the company's stock Bio Path Holdings (BPTH)")
RSI 14 Market Segment - Cancer blood
Bio-Path Holdings is an oncology company developing the DNAbilize® platform for delivering RNA therapeutics. Their drugs target cancer-causing proteins (for example, in leukemia). This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated.
RSI 14 for the overall market
For Bio-Path Holdings, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BPTH (Bio Path Holdings)
Bio-Path Holdings is a biotech company developing a platform (DNAbilize) for delivering RNA-based therapies to treat blood cancers. This chart shows the average 12-month analyst forecast, representing their collective speculative bet on the success of this early-stage R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BPTH-Bio-Path-Holdings&v=1772592098140 "A chart showing analyst consensus forecasts for the expected stock price. BPTH (Bio Path Holdings)")
The difference between the consensus estimate and the actual stock price BPTH (Bio Path Holdings)
Bio-Path (BPTH) is a biotech company developing a unique antisense R&D platform (DNAbilize) for the treatment of blood cancer (leukemia). This chart measures the gap between the current price and the consensus target price. It shows how much confidence experts have in this complex yet innovative scientific technology and its R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BPTH-Bio-Path-Holdings&v=1772592098176 "A chart showing the difference between the consensus forecast and the actual stock price. BPTH (Bio Path Holdings)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Bio-Path (BPTH) is a biotech company developing a unique antisense DNA therapy (the DNAbilize platform) for the treatment of blood cancer. This chart shows general expectations for the blood cancer sector. It reflects whether experts believe in this complex R&D platform or consider it too risky.
Analysts' consensus forecast for the overall market share price
Bio-Path Holdings (BPTH) is an early-stage biopharmaceutical company focused on treating blood cancer (leukemia). This is a highly speculative science. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bio Path Holdings
Bio-Path is a biotech R&D company focused on blood cancer. Their signature feature isn't the drug itself, but their delivery technology (DNAbilize), which packages antisense (RNAi) drugs in lipids (fat) to deliver them inside cancer cells. This chart is a pure R&D barometer. It doesn't reflect revenue, but rather a speculative valuation of their (very risky) pipeline.
AKIMA Market Segment Index - Cancer blood
Bio-Path Holdings is an oncology company with unique antisense technology. Their drugs are designed to block the production of harmful proteins within cancer cells, causing their death. This chart compares their composite index to the sector, showing how their gene-based approach to blood cancer compares to others.
The AKIM Index for the overall market
Bio-Path Holdings is a biotech company developing DNAbil technology (liposomal delivery of antisense oligonucleotides) for cancer treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this long-term scientific story compares to overall economic trends.
